Display options
Cite
Li-Ng M, Verbalis JG. Conivaptan: Evidence supporting its therapeutic use in hyponatremia. Core Evid. 2010;4:83-92doi: 10.2147/ce.s5997.
Li-Ng, M., & Verbalis, J. G. (2010). Conivaptan: Evidence supporting its therapeutic use in hyponatremia. Core evidence, 483-92. https://doi.org/10.2147/ce.s5997
Li-Ng, Melissa, and Verbalis, Joseph G. "Conivaptan: Evidence supporting its therapeutic use in hyponatremia." Core evidence vol. 4 (2010): 83-92. doi: https://doi.org/10.2147/ce.s5997
Li-Ng M, Verbalis JG. Conivaptan: Evidence supporting its therapeutic use in hyponatremia. Core Evid. 2010 Jun 15;4:83-92. doi: 10.2147/ce.s5997. PMID: 20694067; PMCID: PMC2899773.
Copy Download .nbib Format: NLM
Share it on

Core Evid. 2010 Jun 15;4:83-92. doi: 10.2147/ce.s5997.

Conivaptan: Evidence supporting its therapeutic use in hyponatremia.

Core evidence

Melissa Li-Ng, Joseph G Verbalis

Affiliations

  1. Division of Endocrinology and Metabolism, Georgetown University Medical Center, Washington, DC, USA.

PMID: 20694067 PMCID: PMC2899773 DOI: 10.2147/ce.s5997

Abstract

INTRODUCTION: The available treatment options for euvolemic and hypervolemic hyponatremia are limited, and consist mainly of fluid restriction, diuresis, or hypertonic solutions. Most of these therapies are neither well tolerated nor totally effective, and many are associated with significant adverse effects. Vasopressin receptor antagonists, also known as vaptans, are a new class of agents that now offer an additional treatment option for hyponatremic patients. Conivaptan hydrochloride, a competitive antagonist of vasopressin V1a and V2 receptors, is the first agent in this class to be approved for treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.

AIMS: This review critically assesses the evidence that support the use of conivaptan for the treatment of patients with euvolemic and hypervolemic hyponatremia.

EVIDENCE REVIEW CONCLUSION: Conivaptan is effective in raising serum sodium levels in a predictable and safe fashion in euvolemic and hypervolemic hyponatremic patients. Conivaptan provides the first molecularly targeted approach for correcting hyponatremia in hospitalized patients.

Keywords: Conivaptan hydrochloride; arginine vasopressin (AVP); arginine vasopressin (AVP) receptor antagonist; hyponatremia

References

  1. J Am Soc Nephrol. 1994 Feb;4(8):1522-30 - PubMed
  2. JAMA. 2007 Mar 28;297(12):1332-43 - PubMed
  3. Med Clin North Am. 1997 May;81(3):585-609 - PubMed
  4. Eur J Clin Pharmacol. 1999 Nov;55(9):633-7 - PubMed
  5. J Mol Endocrinol. 2002 Aug;29(1):1-9 - PubMed
  6. J Intensive Care Med. 2003 Jan-Feb;18(1):3-8 - PubMed
  7. Hepatology. 2003 Jan;37(1):182-91 - PubMed
  8. Clin Endocrinol (Oxf). 2008 Jul;69(1):159-68 - PubMed
  9. Circulation. 2001 Nov 13;104(20):2417-23 - PubMed
  10. J Clin Endocrinol Metab. 2006 Jun;91(6):2145-52 - PubMed
  11. Am J Med. 2001 May;110(7):582-4 - PubMed
  12. JAMA. 2004 Apr 28;291(16):1963-71 - PubMed
  13. JAMA. 2007 Mar 28;297(12):1319-31 - PubMed
  14. J Am Coll Cardiol. 1983 Jun;1(6):1385-90 - PubMed
  15. Am J Med. 1957 Oct;23(4):529-42 - PubMed
  16. Am J Nephrol. 2007;27(5):447-57 - PubMed
  17. Am J Physiol. 1997 Jan;272(1 Pt 2):F3-12 - PubMed
  18. Eur J Pharmacol. 1999 Sep 17;381(1):23-30 - PubMed
  19. Am J Med. 2006 Jul;119(7 Suppl 1):S30-5 - PubMed
  20. N Engl J Med. 2006 Nov 16;355(20):2099-112 - PubMed
  21. Curr Opin Investig Drugs. 2002 Jan;3(1):89-95 - PubMed
  22. Kidney Int. 2006 Jun;69(12):2124-30 - PubMed
  23. Am Heart J. 2003 Jan;145(1):179-86 - PubMed
  24. J Am Coll Cardiol. 1994 Sep;24(3):583-91 - PubMed
  25. Am J Nephrol. 2006;26(6):579-89 - PubMed
  26. Gastroenterology. 2003 Apr;124(4):933-9 - PubMed
  27. Am J Med. 2007 Nov;120(11 Suppl 1):S1-21 - PubMed
  28. Clin J Am Soc Nephrol. 2006 Nov;1(6):1154-60 - PubMed

Publication Types